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Abstract
The WISEWOMAN program targets low-income under- 
and uninsured women aged 40–64 years for screening and 
interventions aimed at reducing the risk of heart disease, 
stroke, and other chronic diseases. The program enters its 
third phase on June 30, 2008. Design issues and results 
from Phase I and Phase II have been published in a series 
of  papers.  We  summarize  remaining  challenges,  which 
were  identified  through  systematic  research  and  evalu-
ation. Phase III will address these challenges through a 
number of new initiatives such as allowing interventions 
of different intensities, taking advantage of resources for 
promoting  community  health,  and  providing  evidence-
based  interventions  through  the  program’s  Center  of 
Excellence. Finally, we provide a framework and vision so 
that organizational, community, and other partners can 
make the case for the importance of the program to their 
communities and for what is needed to make it work.
Background
Lessons learned
The  Well-Integrated  Screening  and  Evaluation  for 
Women Across the Nation (WISEWOMAN) (1,2) program, 
funded by the Centers for Disease Control and Prevention 
(CDC), targets low-income under- and uninsured women 
aged 40–64 years. Aimed at reducing the risk of heart dis-
ease, stroke, and other chronic diseases, WISEWOMAN 
provides screening for high blood pressure, hypercholes-
terolemia, and abnormal glucose levels and interventions 
to  help  women  eat  more  healthfully,  increase  physical 
activity, and quit smoking. The program refers women 
with  abnormal  screening  values  for  treatment  and  at 
1-year follow-up visits provides feedback to participants 
and their providers about changes in risk factor profiles 
(2). WISEWOMAN, which works in conjunction with the 
National  Breast  and  Cervical  Cancer  Early  Detection 
Program (NBCCEDP), has now reached more than 75,000 
women.
Phase I of WISEWOMAN (1995–1998), which focused 
on research only, tested whether enhanced lifestyle inter-
ventions were more effective than lifestyle interventions 
using minimal or usual care. Design issues and results 
from this phase have been covered in a series of articles (3-
6). During Phase II (1999–2007), state and tribal organiza-
tions could apply for either research funding or standard 
project funding, which allowed more flexibility in adapting 
previously  tested,  evidence-based  interventions  to  local 
settings and made fewer research demands. Fifteen proj-
ects are now funded (Table 1), and results and overviews of 
12 of these have been published (2,7-12). Lessons learned 
from Phase I (13) and Phase II are briefly summarized in 
Table 1. Implementation of Phase III is scheduled to begin 
June 30, 2008. We focus here on the use of lessons learned 
as the basis for planning the future of WISEWOMAN.
Methods used to identify lessons learned
WISEWOMAN has identified lessons learned through 
randomized controlled trials (5,6), nonrandomized group-
assigned  trials  (3),  quasi-experimental  studies  such  as 
pretest  and  posttest  comparisons  (8,9),  cross-sectional 
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studies employing benchmarks to measure performance 
(CDC, unpublished report, 2007), and case studies involv-
ing interviews with key stakeholders (11,13). Case studies 
were often mixed with analyses of benchmarks or outcome 
data to provide a richer description than could be obtained 
from quantitative data alone (11).
In  Phase  II,  performance  indicators  for  nonresearch 
projects  included  screening  2500  women  annually  and 
ensuring that 75% of screened participants began the life-
style intervention, that 60% of women starting the inter-
vention completed it, that 75% of women screened were 
rescreened within 10–14 months, and that 95% of women 
with  systolic  blood  pressure  >180  mm  Hg  or  diastolic 
blood pressure >110 mm Hg were seen within 1 week of 
screening. Programs varied substantially in their ability 
to meet performance indicators. For example, the number 
of annual screenings performed by programs ranged from 
449 to 5629, and initiation of lifestyle interventions ranged 
from  16%  of  participants  in  the  lowest-performing  pro-
gram to 100% in the highest-performing program (CDC, 
unpublished report, 2007). Although the highest-perform-
ing programs demonstrated that most of the performance 
indicators  are  achievable,  the  WISEWOMAN  program 
decided to revisit the feasibility of using these indicators 
and to identify obstacles to reaching them.
In an example of the mixed-methods approach, inves-
tigators conducted case studies of the sites that had the 
highest and the lowest public health impact within a select 
number of states and tribes (11,12). From this analysis, 
investigators identified practices that appeared to increase 
the  chances  of  a  successful  project.  These  practices  are 
described  in  the  WISEWOMAN  Best  Practices  Toolkit 
(www.cdc.gov/wisewoman).
WISEWOMAN  participants  who  returned  for  1-year 
evaluations showed significant reductions in systolic blood 
pressure (−0.9%. P < .05), total cholesterol (−1.8%, P < .05), 
smoking (−8.0%, P < .05), and 10-year risk of coronary 
heart disease (−4.9%, P < .05) (CDC, unpublished data, 
2007). In the subgroup with abnormal screening values at 
baseline, these reductions were even more striking (8). In 
contrast, changes in weight and blood glucose values were 
both clinically and statistically insignificant, highlighting 
a need to strengthen the program in those areas (8). The 
importance of these risk factors is underscored by findings 
from the Diabetes Prevention Program Research Group 
(14),  which  showed  weight  loss  and  improved  nutrition 
and physical activity to be more likely than medication 
alone to delay the onset of diabetes.
As  a  result  of  lessons  learned  in  the  previous  phase, 
Phase  II  projects  were  strongly  encouraged  to  use  the 
socioecologic model (15), which includes the strengthening 
of linkages at the community and organizational levels. 
Success stories have been used as an additional method for 
identifying these types of lessons learned (16-18).
Key Challenges
Phase III will address the following challenges that were 
identified in phases I and II:
• Maximize the number of women who receive program 
services (e.g., screening, lifestyle interventions, referral, 
follow-up).
• Target  geographic  areas  in  each  state  and  tribe  with 
the highest death rates and hospital discharge rates for 
heart disease and stroke.
• Deliver effective behavioral counseling based on sound 
theoretical approaches.
• Tailor lifestyle interventions according to degrees of risk 
for  heart  disease  and  stroke  and  readiness-to-change 
behaviors.
• Maximize  the  number  of  women  being  reassessed  to 
determine  whether  their  risk  for  heart  disease  and 
stroke has decreased and their health behaviors have 
improved.
• Collaborate  with  state,  local,  and  community  part-
ners who can make policy, environmental, and system 
changes  that  support  the  adoption  and  maintenance 
of heart-healthy behaviors by underserved populations 
where they work, live, and play.
These challenges will be addressed through the require-
ments  published  in  funding  announcements,  stronger 
program  guidance,  clarified  program  vision  and  goals, 
new performance indicators, and evidence-based technical 
assistance and training. As in the past, WISEWOMAN 
will use a variety of evaluation methods to determine the 
degree to which these key challenges have been met.
Solutions for the Future
Most  of  the  remainder  of  this  article  addresses  two   
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program  and  ensuring  the  effectiveness  of  its  projects. 
Reach and effectiveness are the two criteria most directly 
related to determining WISEWOMAN’s impact and thus 
merit extensive discussion. First, however, we focus on the 
importance of having a clear programmatic vision.
Clarifying the vision
Recent  evidence  from  implementation  of  the  Chronic 
Care Model (19,20) suggests that multilevel approaches 
such as WISEWOMAN’s work better than approaches that 
focus on one level alone. Legislative language, however, 
stipulates that 60% of dollars given to WISEWOMAN proj-
ects must be used for services to individual participants. 
Consequently, implementing the program at multiple lev-
els is an ongoing challenge. Creating strong partnerships 
and links with organizations and communities to establish 
changes in the health system and in policy is key to solving 
this challenge.
The WISEWOMAN program employs the models used 
by Abrams et al (21) and Glasgow et al (22) to evaluate 
public health impact. In its early phases, WISEWOMAN 
tended to focus heavily on the effectiveness of a lifestyle 
intervention  (e.g.,  1-year  reductions  in  blood  pressure 
and  cholesterol),  but  as  the  program  expanded  into 
nonresearch settings, projects began requesting a wider 
definition of success. Two appropriate new measures are 
the public health impact of a project and its value. Impact 
can be defined as either reach multiplied by effectiveness 
(21) or a variant that adds dimensions of adoption, imple-
mentation,  and  maintenance  (22).  Maximum  impact  is 
most likely when a large number of participants achieve 
small to moderate improvements in risk factors (i.e., effec-
tiveness)  than  when  fewer  participants  achieve  greater 
improvements. A criterion of effectiveness alone is inap-
propriate  for  WISEWOMAN,  because  a  program  might 
be extremely effective but serve only a small percentage 
of eligible women (i.e., have limited reach). Value, the sec-
ond measure of success, which we define as public health 
impact at a reasonable cost, is similar to cost-effectiveness, 
except that we measure the cost of achieving a certain 
impact (21) rather than effectiveness.
Another  issue  to  be  clarified  involves  approaches  to 
implementing an intervention. Projects were required to 
select an evidence-based intervention, but ongoing guid-
ance was not provided on tailoring interventions to new 
target populations or unique settings. Consequently, many 
projects did not faithfully implement the elements of their 
intervention  that  were  credited  with  its  effectiveness. 
Faithfully  implementing  these  core  elements  is  impor-
tant, as demonstrated by the translation work of CDC’s 
Division  of  HIV/AIDS  Prevention,  the  Center  on  AIDS 
and Community Health, and the Academy for Educational 
Development (23) (www.effectiveinterventions.org).
The WISEWOMAN program is complex, drawing on mul-
tiple theoretical models including the ecologic approaches 
defined in the socioecologic model; change theories aimed 
at altering behavior and organizational and community 
practices; and models that underscore the importance of 
creating  public  health  impact  through  increased  reach 
and  effectiveness.  Although  WISEWOMAN  stressed  all 
of these models in the past, the program did not have an 
organizing  framework  showing  how  the  various  models 
related  to  each  other.  The  new  framework  (Figure  1), 
which brings together these models, can be used by any 
public health program aimed at changing behavior and 
policy. As indicated in the figure, WISEWOMAN will use 
the  socioecologic  framework  to  identify  partners  work-
ing  at  individual,  organizational,  community,  and  state 
levels to ensure that all are working to maximize public 
health  impact.  The  program  is  committed  to  evidence-
based interventions and will advise projects on creating 
change at the behavioral, organizational, community and 
environmental, and policy levels. Finally, WISEWOMAN 
will expand its focus from the effectiveness of interven-
tions alone to include public health impact and the cost of 
achieving such impact (i.e., value).
From the beginning, the WISEWOMAN program has 
been  delivered  as  a  multicomponent  intervention  that 
comprises 1) screening of risk factors for cardiovascular 
disease and other chronic diseases, 2) lifestyle interven-
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Figure 1. Organizing framework, WISEWOMAN, United States. VOLUME 5: NO. 2
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tions,  3)  assurance  of  access  to  needed  treatment  and 
medication,  and  4)  follow-up  visits  for  monitoring  and 
evaluation.  These  components  are  required  by  congres-
sional  legislation.  The  clinical  guidelines  that  are  the 
source of the evidence for each of these four components 
(Table 2) include the use of a multicomponent approach 
for maximum clinical effectiveness. Instead of focusing on 
determining which component works best, WISEWOMAN 
is committed to strengthening all four components.
Maximizing the program’s reach
One approach to expanding the reach of WISEWOMAN 
is to better match participants’ needs with the program 
resources. Various interventions tailored to participants’ 
degrees of risk or readiness to change might be the best 
way  to  proceed,  or  interventions  might  be  designed  to 
reduce  costs  per  woman  served.  During  Phase  II,  CDC 
asked that all participants be required to attend the same 
lifestyle intervention regardless of how strong their risk 
factors were or how ready they were to change. For many 
reasons, however, designing only one intervention for all 
women can limit a program’s reach. Furthermore, women 
with normal screening values will most likely not need an 
intensive intervention designed to control risk factors, nor 
is it reasonable or cost-effective to ask a woman who is 
not ready to change to participate in a costly intervention. 
Referring women with highly abnormal screening values 
to low-intensity interventions that may not help control 
their risk factors is also likely to be ineffective.
Because women often describe time as the major barrier 
to  participation  in  public  health  programs  (29),  asking 
them  to  invest  time  in  a  program  unnecessarily  is  not 
reasonable. Abrams et al (21) have proposed a stepped-
care approach in which participants begin with the least 
intensive  intervention  necessary,  and  only  those  whose 
risk is not reduced are offered more intensive interven-
tions. Abrams et al also discuss an approach that matches 
programs  to  women  by  their  readiness  to  change  and 
the extent of their risk factors. Other behavioral scien-
tists have suggested a variation of this approach, which 
is usually called triaging (30). Beginning in June 2008, 
the  WISEWOMAN  program  will  ask  state  and  tribal 
programs to use these and other new models, including 
changing the mode of delivery to include approaches such 
as self-help; video, computer-, or Web-based delivery; face-
to-face assessments; and group counseling.
Ensuring the effectiveness of strategies for change
Scientists  have  debated  the  degree  to  which  every 
aspect of an intervention must be delivered exactly as it 
was in the randomized trial that demonstrated its effec-
tiveness (31). An extreme argument is that any change 
to the original intervention, including translating it into 
another language and making it culturally appropriate, 
should require a new randomized trial, even if the core 
elements remain the same. Other scientists contend that 
if the core elements remain intact, interventions can be 
adapted to ensure fit to the local context and setting (23). 
In the future, WISEWOMAN projects will use the latter 
approach as part of an effort to maximize both effective-
ness  and  the  ability  to  tailor  the  intervention  for  local 
settings.  To  accomplish  this,  we  will  review  evidence-
based interventions and identify the core elements that 
must be faithfully implemented and other characteristics 
that increase the probability of success. We will then dis-
seminate intervention packages that can be downloaded 
from a Web site. Practitioners will be able to choose from 
a  menu  of  WISEWOMAN  Interventions  with  Sound 
Evidence  (WISE  Interventions,  www.wiseinterventions.
org). Evaluation will focus on monitoring the implementa-
tion of core elements.
For the practitioner, CDC’s state and tribal partners, 
and CDC staff, knowing how to deliver a program is often 
the  most  difficult  challenge.  The  various  levels  of  the 
socioecologic model dictate different strategies for change. 
For  example,  the  WISEWOMAN  program  endorses  the 
5A’s  strategy  (Assess,  Advise,  Agree,  Assist,  Arrange) 
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Figure 2. Example of an individual behavior change model, WISEWOMAN, 
United States. 
NBCCEDP indicates National Breast and Cervical Cancer Early Detection 
Program(25)  for  creating  change  at  the  individual  level  (Figure 
2). Furthermore, allowing for multiple levels of stratifica-
tion according to motivation and risk is consistent with 
the WISEWOMAN vision to create more appropriate and 
effective interventions.
At the organizational and community level, we will use 
the following steps advocated by Kotter (26) (Figure 3) to 
encourage adoption, faithful implementation, and mainte-
nance of a project: 1) establish a sense of urgency, 2) form 
a powerful coalition, 3) create a vision, 4) communicate 
the vision, 5) empower others to act on the vision, 6) plan 
for  and  create  short-term  wins,  7)  consolidate  improve-
ments and produce more change, and 8) institutionalize 
new approaches. To implement a WISEWOMAN project 
effectively, a local health organization (e.g., clinic, health 
department) will need, for example, to focus on preventive 
health care for under- and uninsured women as a key part 
of its mission, to use or adapt an intervention so that it 
is appropriate while remaining effective, to enhance use 
of community resources, and to create the organizational 
changes  essential  for  implementing  and  sustaining  the 
program over time.
Creating community and policy changes using Kotter’s 
approach means first establishing a sense of urgency among 
community leaders about providing financially disadvan-
taged populations with access to resources and ensuring 
social and environmental support through such activities 
as  creating  walkable  environments  in  the  lowest-income 
neighborhoods. For policy changes, the initial task of creat-
ing a sense of urgency can involve issues such as universal 
access to preventive health services and the expansion of 
successful health promotion programs statewide.
Conclusion
When  it  enters  its  implementation  phase  (Phase  III), 
WISEWOMAN  will  be  moving  in  some  new  directions. 
To extend reach and reduce costs, the program will help 
projects  design  interventions  based  on  degrees  of  risk 
and  levels  of  motivation  and  will  ensure  that  projects 
have access to resources for promoting community health. 
These strategies are also likely to increase the effective-
ness of the program. For example, one strategy has CDC 
providing evidence-based interventions and core elements 
through the Center of Excellence that conducts research on 
improving the public health impact of the WISEWOMAN 
program. Another strategy for increasing effectiveness is 
the provision of a clear framework and vision so that orga-
nizational, community, and other partners can make the 
case for why the program is important to their communi-
ties and what is needed to make it work.
Moving in a new direction always presents challenges. 
For WISEWOMAN, some of these challenges are ensuring 
that underfunded sites are not overburdened by having to 
conduct  multiple  interventions,  measuring  readiness  to 
change  when  addressing  multiple  behaviors,  packaging 
new interventions and updating old versions, monitoring 
projects for faithful implementation of core elements, and 
ensuring that women with normal screening values receive 
appropriate  counseling  and  resources.  Acknowledging 
these  challenges,  CDC  looks  forward  to  Phase  III  and 
hopes to be able to demonstrate the impact of these new 
directions through increased services to a greater number 
of women and a reduction in heart disease and stroke.
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Tables
Table 1. Challenges and Strengths Identified by States and Tribes Funded for Research and Nonresearch Projects, 
WISEWOMAN, Phases I and II, United States, 1995–2007
Funded States Challenges Strengths
Phase I (1995-1998): Research 
Arizona
Massachusetts
North Carolina
•  Difficulty integrating clinical and lifestyle inter-
ventions.
•  Difficulty implementing research in public health 
settings.
•  Need to extend reach beyond the individual.
•  Difficulty developing organizational structure to 
focus on prevention of risk factors.
•  Often biological outcomes improved in control 
groups, making determining the true effect of 
the lifestyle intervention difficult.
•  High rates of participation in lifestyle interventions.
•  High number of women returning for -year 
rescreening.
•  Comprehensive approach that addresses multiple 
health issues.
•  Linkages to primary health care were strengthened.
•  Innovative behavioral interventions provided.
•  Lifestyle interventions demonstrated improvements 
in nutrition and physical activity.
Phase II (1999-2007): Research and Nonresearch
Research 
Alaska (Southcentral Foundation)
California
Illinois
Iowa
North Carolina
West Virginia
Nonresearch
Alaska (Southeast Alaska Regional Health 
Consortium)
Connecticut
Massachusetts
Michigan
Minnesota
Missouri
Nebraska
South Dakota
Vermont
•  Difficulty ensuring all women enroll in and com-
plete lifestyle interventions.
•  Difficultly ensuring rescreening at 0- 
months.
•  Challenges in reaching the targeted number of 
annual screenings (2500).
•  Benchmarks for performance indicators may 
have been unrealistic.
•  Diabetes prevention and weight-loss strategies 
need strengthening.
•  Lifestyle interventions adapted without evidence 
base.
•  Nonresearch projects provided greater flexibility and 
decreased research demands.
•  More successful implementation of socioecologic 
model.
•  High-performing sites provided opportunities for 
case studies to determine best practices.
•  Many risk factors reduced significantly.
•  Wide range of innovative interventions implement-
ed.
•  Some programs were able to go statewide.VOLUME 5: NO. 2
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Table 2. Clinical Guidelines that Support the Four WISEWOMAN Components, United States
Component Clinical Guidelines
Cardiovascular risk factor screening Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 
200 (ATP-III) 
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure, 200 (JNC 7)
Guide to Clinical Preventive Services, 2005
Lifestyle intervention ATP-III, JNC 7, and Guide to Clinical Preventive Services, 2005 (for dietary counseling of adults with risk fac-
tors) 
Guide to Community Preventive Services, 200 (for Tobacco Quit Lines)
Guide to Community Preventive Services, 200 (for physical activity programs adapted for individual needs)
Treatment and medication ATP-III, JNC 7
Rescreening for monitoring and evalu-
ation
Guide to Clinical Preventive Services, 2005
 
ATP indicates Adult Treatment Panel.